GT Biopharma posts $3.53M Q3 loss, going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
GT Biopharma, Inc. (GTBP) reported no revenue and a net loss of $3.531 million for the third quarter ended September 30, 2026, compared with net income of $8.299 million a year earlier. For the first nine months, net loss was $10.882 million versus $22.646 million in 2025. Cash and cash equivalents were $9.923 million at September 30, while operating activities used $9.366 million during the nine-month period; financing activities provided $12.478 million. GTB-3650’s initial clinical study had enrolled its first four cohorts.
The company recorded $7.64 million of net proceeds from its September 2026 Series M preferred-stock and warrant transaction. It has no product candidates approved for sale and reported that its losses and operating cash use raised substantial doubt about its ability to continue as a going concern within one year of issuing these statements. Without additional financing, it said its cash resources would not fund anticipated operations for that period. GTBP also reported regaining Nasdaq’s $1.00 minimum bid-price compliance on September 22, 2026, after closing above $1.00 for at least ten consecutive business days.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss fell to $10.882 million from $22.646 million.
Negative
- Major pointSubstantial doubt remains about the company’s ability to continue as a going concern within one year.
- Moderate pointThird-quarter results shifted to a $3.531 million loss from $8.299 million income.
- Minor pointOperating cash use rose to $9.366 million from $8.893 million.
Filing Explained
The November 11 vote cleared the approval condition, but Series M conversions and warrant exercises—not the vote—determine actual additional shares issued.
This 10-Q reports that the September Series M financing remains represented by convertible preferred stock and warrants, so its potential common-share issuance is not yet complete. As of
The Series M securities have full-ratchet anti-dilution protections. At
After quarter-end, Series L conversions added 30,004 common shares through
Key Figures
Key Terms
Tri-specific Killer Engager technical
natural killer cells medical
full-ratchet price and anti-dilution protections financial
Greenshoe Rights financial
going concern financial
Investigational New Drug regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were GTBP’s results for the first nine months of 2026?
How much cash did GTBP have at September 30, 2026?
Why did GTBP report substantial doubt about continuing as a going concern?
What did GTBP receive from the September 2026 Series M financing?
Did GTBP regain Nasdaq’s minimum bid-price compliance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For
the quarterly period ended
| Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from __________ to ____________.
Commission
File Number
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification Number) |
N/A1
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of exchange on which registered | ||
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 10, 2026, the registrant had
1
Effective as of July 1, 2024, the Company became a fully remote
company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act
of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company’s
principal executive offices may be directed to
GT BIOPHARMA, INC.
FORM 10-Q
For the Three and Nine Months Ended September 30, 2026
Table of Contents
| Page | ||
| PART I FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | |
| Condensed Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 | 3 | |
| Condensed Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (Unaudited) | 4 | |
| Condensed Statements of Stockholders’ Equity (Deficit) and Mezzanine Equity for the three and nine months ended September 30, 2026 and 2025 (Unaudited) | 5 | |
| Condensed Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (Unaudited) | 7 | |
| Notes to Unaudited Condensed Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 20 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28 |
| Item 4. | Controls and Procedures | 28 |
| PART II OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 29 |
| Item 1A. | Risk Factors | 29 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29 |
| Item 3. | Defaults Upon Senior Securities | 29 |
| Item 4. | Mine Safety Disclosures | 29 |
| Item 5. | Other Information | 29 |
| Item 6. | Exhibits | 30 |
| SIGNATURES | 32 | |
| 2 |
GT BIOPHARMA, INC.
Condensed Balance Sheets
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash | ||||||||
| Deferred offering costs | ||||||||
| Prepaid expenses and other current assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Warrant liability | — | |||||||
| Total Current Liabilities | ||||||||
| Stockholders’ Equity | ||||||||
| Convertible Preferred stock, par value $ | — | |||||||
| Series L, | — | — | ||||||
| Series M, | — | — | ||||||
| Preferred stock value | — | — | ||||||
| Common stock, par value $ | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Equity | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 3 |
GT BIOPHARMA, INC.
Condensed Statements of Operations
The Three Months | The Nine Months | |||||||||||||||
| Ended September 30, | Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Revenues | $ | — | $ | — | $ | — | $ | — | ||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other Income (Expense) | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | — | ( | ) | — | ||||||||||
| Loss on initial recognition of Greenshoe Rights liability | — | — | — | ( | ) | |||||||||||
| Change in fair value of Greenshoe Rights liability | — | — | ||||||||||||||
| Change in fair value of warrant liability | — | |||||||||||||||
| Gain on settlement of vendor payable | — | — | — | |||||||||||||
| Other income | — | — | — | |||||||||||||
| Total Other Income (Expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Net Income (Loss) | ( | ) | ( | ) | ( | ) | ||||||||||
| Dividend on preferred stock | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Deemed dividend | — | ( | ) | ( | ) | ( | ) | |||||||||
| Net Income (Loss) attributable to common stockholders | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Net Income (Loss) Per Share - Basic and Diluted | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Weighted average common shares outstanding - basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 4 |
GT BIOPHARMA, INC.
Condensed Statements of Stockholders’ Equity (Deficit)
For The Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
Series C Preferred Shares |
Series L Preferred Shares | Series M Preferred Shares | Common Shares | Additional Paid in | Accumulated | Total Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance, June 30, 2026 | $ | $ | - | - | $ | - | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Issuance of common stock in settlement of vendor payable | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series C convertible preferred stock | ( | ) | ( | ) | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
| Conversion of Series L convertible preferred stock | - | - | ( | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Series M convertible preferred stock and warrants issued for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series M convertible preferred stock | - | - | - | ( | ) | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Dividend on convertible preferred stock | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | - | $ | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
Series C Preferred Shares |
Series L Preferred Shares | Series M Preferred Shares | Common Shares | Additional Paid in | Accumulated | Total Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance, December 31, 2025 | $ | $ | - | - | $ | - | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Exercise of warrants for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Fair value of pre-funded warrants issued for services and exercised | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Issuance of common stock in settlement of vendor payable | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series C convertible preferred stock | ( | ) | ( | ) | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
| Series L convertible preferred stock and warrants issued for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series L convertible preferred stock | - | - | ( | ) | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||||||||||
| Series M convertible preferred stock and warrants issued for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series M convertible preferred stock | - | - | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Dividend on convertible preferred stock | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | - | $ | - | $ | - | $ | - | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 5 |
GT BIOPHARMA, INC.
Condensed Statements of Stockholders’ Equity (Deficit) and Mezzanine Equity
For The Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | Shares | Amount | ||||||||||||||||||||||||||||||||||
Series C Preferred Shares | Series L Preferred Shares | Common Shares | Additional Paid in | Accumulated | Total Stockholders’ Equity | Mezzanine Equity Series L Preferred Shares | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | Shares | Amount | ||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Mezzanine equity reclassification | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Series L convertible preferred stock issued for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series L convertible preferred stock into common stock | - | - | ( | ) | - | ( | ) | - | - | - | - | |||||||||||||||||||||||||||||||||
| Dividend on Series L convertible preferred stock | - | - | - | - | - | - | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Reclassification of Greenshoe Rights liability to equity | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | - | $ | $ | $ | ( | ) | $ | - | $ | - | ||||||||||||||||||||||||||||||||
Series C Preferred Shares | Series L Preferred Shares | Common Shares | Additional Paid in | Accumulated | Total Stockholders’ Equity | Mezzanine Equity Series L Preferred Shares | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | Shares | Amount | ||||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | - | - | ||||||||||||||||||||||||||||||
| Exercise of warrants for cash and inducement warrants, net | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Series L convertible preferred stock and warrants issued for cash, net | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Conversion of Series L convertible preferred stock into common stock | - | - | ( | ) | - | ( | ) | - | - | - | - | |||||||||||||||||||||||||||||||||
| Issuance of prefunded warrants in settlement of vendor payable | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance and exercise of prefunded warrants for ELOC fee | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Issuance of common stock and warrants for services | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Issuance of warrants for VRT waiver | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Dividend on Series L convertible preferred stock | - | - | - | - | - | - | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||
| Dividend on convertible preferred stock | - | - | - | - | - | - | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Reclassification of Greenshoe Rights liability to equity | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | - | - | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | - | $ | $ | $ | ( | ) | $ | - | - | |||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 6 |
GT BIOPHARMA, INC.
Condensed Statements of Cash Flows
| 2026 | 2025 | |||||||
| For The Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Fair value of vested stock options | ||||||||
| Issuance of warrants for VRT waiver | — | |||||||
| Loss on initial recognition of Greenshoe Rights liability | — | |||||||
| Change in fair value of Greenshoe Rights liability | — | ( | ) | |||||
| Change in fair value of warrant liability | ( | ) | ( | ) | ||||
| Gain on settlement of vendor payable | — | ( | ) | |||||
| Gain on extinguishment of debt | — | ( | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| (Increase) Decrease in prepaid expenses and deferred offering costs | ( | ) | ||||||
| Increase (Decrease) in accounts payable and accrued expenses | ( | ) | ||||||
| Net Cash Used in Operating Activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | — | — | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Exercise of warrants for cash, net | ||||||||
| Proceeds from issuance of Series L convertible preferred stock and warrants, net | ||||||||
| Proceeds from issuance of Series M convertible preferred stock and warrants, net | — | |||||||
| Dividend on convertible preferred stock | ( | ) | ( | ) | ||||
| Net Cash Provided by Financing Activities | ||||||||
| Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash | ( | ) | ||||||
| Cash and Cash Equivalents and Restricted Cash at Beginning of Period | ||||||||
| Cash and Cash Equivalents and Restricted Cash at End of Period | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid during the period for: | ||||||||
| Interest | $ | — | $ | — | ||||
| Income taxes | $ | — | $ | — | ||||
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Fair value of vested warrants issued in Series L conv. preferred stock transaction | $ | — | $ | |||||
| Fair value of prefunded warrants issued for ELOC fee | $ | — | $ | |||||
| Fair value of common stock and warrants issued for services | $ | $ | ||||||
| Fair value of prefunded warrants and common stock to settle vendor payable | $ | $ | ||||||
| Dividend on convertible preferred stock | $ | $ | ||||||
| Reclassification of Greenshoe Rights liability to equity | $ | — | $ | |||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 7 |
GT BIOPHARMA, INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
Note 1 – Organization and Going Concern Analysis
Organization
GT Biopharma, Inc. (the “Company”) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) platforms. The Company’s TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”).
The corporate predecessor of GT Biopharma, Inc., Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.
Throughout this Quarterly Report on Form 10-Q, the terms “GTBP,” “we,” “us,” “our,” “the Company” and “our Company” refer to GT Biopharma, Inc.
The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.
Going Concern Analysis
The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, $
The unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on the basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.
The Company has evaluated the significance of the uncertainty regarding the Company’s financial condition in relation to its ability to meet its obligations, which has raised substantial doubt about the Company’s ability to continue as a going concern. While it is very difficult to estimate the Company’s future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs and the ability to continue operations.
| 8 |
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 2, 2026 (the “2025 Annual Report”). The balance sheet as of December 31, 2025 included herein, was derived from the audited financial statements as of that date.
In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.
The comparative financial information for the three and nine months ended September 30, 2025 reflects the restatement described in Note 10 to the Company’s financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025.
Accounting Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.
Cash Equivalents
The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2026 and December 31, 2025, total cash equivalents which
consist of money market funds, amounted to approximately $
Cash equivalents consist entirely of investments in U.S. Treasury money market funds that are not insured by the FDIC; however, these funds invest solely in direct obligations of the U.S. government. The Company believes that the credit risk associated with these instruments is minimal.
Restricted Cash
As of September 30, 2026, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The Company’s restricted cash is deposited in a financial institution and held as collateral for a credit card agreement with the same financial institution.
Deferred Offering Costs
The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company’s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2026, there was $
Common Stock (September 2026 Reverse Stock Split)
On
September 8, 2026, the Company effectuated a reverse stock-split of its Common Stock, at a ratio of
As
a result of the reverse stock split, every twenty-five (
Simultaneously
with the reverse stock split, the total authorized shares of capital stock were reduced from
Proportionate adjustments have been made to the Company’s outstanding convertible securities, warrants, stock options and restricted stock. The number of shares of Common Stock into which these outstanding securities are convertible or exercisable will be adjusted proportionately as a result of the reverse stock split. The conversion prices of any outstanding convertible securities and the exercise prices of any outstanding warrants or stock options will also be proportionately adjusted in accordance with the terms of those securities and the Company’s equity incentive plans.
| 9 |
All share and per share information within this report has been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.
Stock-Based Compensation
The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.
Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
Research and Development Expenses
Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Purchased materials that have an alternative future use are classified as a prepaid expense and periodically reviewed.
Net Loss Per Share
Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants, the conversion of Series L 10% Convertible Preferred Stock (the “Series L Preferred Stock”), and the conversion of Series M 10% Convertible Preferred Stock (the “Series M Preferred Stock”), have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
During
the nine months ended September 30, 2026, the Company recorded dividends on Series L and Series M Preferred Stock of $
The following Common Stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:
Schedule of Anti-dilutive Securities
September 30, 2026 (Unaudited) | September 30, 2025 (Unaudited) | |||||||
| Series L Preferred Stock 1 | 1 | 2 | ||||||
| Series M Preferred Stock 3 | — | |||||||
| Greenshoe Rights - Series L Preferred Stock | 1 | 2 | ||||||
| Greenshoe Rights - Series M Preferred Stock 3 | — | |||||||
| Options to purchase Common Stock | ||||||||
| Warrants to purchase Common Stock | ||||||||
| Total anti-dilutive securities | ||||||||
| 1 | |
| 2 | |
| 3 |
Concentration
Cash
is deposited in two financial institutions. The cash balance in one of these financial institutions is not insured
by any agency. The cash balance held at the other financial institution at times may be in excess of Federal Deposit
Insurance Corporation (“FDIC”) insurance limits of up to $
| 10 |
Segment Information
The Company’s Chief Executive Officer and President (“CEO”) is our chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the financial results of the Company.
Recent Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.
The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.
Note 3 – Stockholders’ Equity (Deficit)
The
Company’s authorized capital as of September 30, 2026 was
2025 Private Placement of Equity Facility (the “Committed Equity Facility”)
On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the “Common Shares
Purchase Agreement”) with investors (collectively, the “Investors”) relating to the Committed Equity Facility. Pursuant
to the Common Shares Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $
Sales of the shares of Common Stock to the Investors under the Common Shares Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading price of the Common Stock and determinations by the Company regarding the use of proceeds from the sale of such shares of Common Stock. The net proceeds from any sales under the Common Shares Purchase Agreement will depend on the frequency with, and prices at, which the shares of Common Stock are sold to the Investors.
The
purchase price of the shares of Common Stock that the Company elects to sell to the Investors pursuant to the Common Shares Purchase
Agreement will be
In
connection with the execution of the Common Shares Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants
to purchase an aggregate of
2025 Warrant Inducement Transaction
On
February 26, 2025, the Company received gross proceeds of $
The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to
| 11 |
The Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company’s own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement agent warrants is classified as equity.
The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $
Preferred Stock
On September 2, 2026, the Company filed Certificates of Elimination (collectively, the “Certificates of Elimination”) to the Restated Certificate of Incorporation of the Company (the “Charter”) with the Secretary of State of the State of Delaware. The Certificates of Elimination eliminated from the Charter all matters set forth in the applicable Certificates of Designations with respect to the following series of preferred stock: (i) the Series A Preferred Stock; (ii) the Series B Preferred Stock; (iii) the Series C Preferred Stock; (iv) the Series D Preferred Stock; (v) the Series E Preferred Stock; (vi) the Series F Preferred Stock; (vii) the Series G Preferred Stock; (viii) the Series H Preferred Stock; (ix) the Series I Preferred Stock; (x) the Series J-1 Preferred Stock; and (xi) the Series K Preferred Stock (collectively, the “Eliminated Preferred Stock”).
Series C Preferred Stock
Prior
to filing the Certificate of Elimination regarding the Series C Preferred Stock all
Series L Preferred Stock and Warrants
The Company previously issued shares of Series L Preferred Stock and related warrants (the “2025 Warrants”) pursuant to a securities purchase agreement entered into in May 2025, as more fully described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
As
of September 30, 2025, there were
Series L Preferred Stock and Warrant Activity During the Nine Months Ended September 30, 2026
During
the nine months ended September 30, 2026, holders exercised certain additional purchase rights issued pursuant to the May 2025
private placement (the “Series L Greenshoe Rights”) and purchased
The reduction in the conversion price constituted a dilutive issuance under the terms of the 2025 Warrants. Accordingly, the exercise price of the outstanding 2025 Warrants was reduced, and the number of shares underlying the 2025 Warrants was increased, such that the aggregate exercise price of the 2025 Warrants remained unchanged.
For
the nine months ended September 30, 2026, the incremental change in the fair value of equity classified instruments upon the reduction
of conversion and exercise prices was determined to be $
Series M Preferred Stock and Warrants
As
of September 30, 2026, there were
On
September 14, 2026, the Company entered into a securities purchase agreement (as amended on September 18, 2026, the “September
2026 Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) providing for the issuance and
sale of (i)
| 12 |
Pursuant
to the September 2026 Securities Purchase Agreement, each Purchaser may elect to purchase up to
On September 14, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series M 10% Convertible Preferred Stock (the “Series M Certificate of Designation”) with the Secretary of State of the State of Delaware.
The
shares of Series M Preferred Stock and 2026 Warrants both have full-ratchet price and anti-dilution protections and are subject to
other adjustments, as further described in the Series M Certificate of Designation or the 2026 Warrants, as applicable, subject,
solely with respect to adjustments in connection with the exercise of Series M Greenshoe Rights. There will not be a floor price;
provided, however, if the Company receives written notice from Nasdaq that a floor price should be implemented, a floor price of
$
In connection with our entry into the September 2026 Securities Purchase
Agreement, on September 14, 2026, we entered into a registration rights agreement with the Purchasers, pursuant to which we agreed to
file a resale registration statement with respect to the public resale of the shares of Common Stock issuable upon conversion of the shares
of Series M Preferred Stock and upon exercise of the 2026 Warrants not later than 30 calendar days after September 14, 2026 and after
each closing of the exercise of a Series M Greenshoe Right in accordance with the September 2026 Securities Purchase Agreement, to become
effective no later than 60 days after September 14, 2026 or each Trigger Date (as defined
in the registration rights agreement), or in the event of a “full review” by the SEC, 90 days after September 14, 2026 or
each Trigger Date. If these deadlines are not met,
Pursuant to the September 2026 Securities Purchase Agreement, the Company
agreed to hold a meeting of its stockholders at the earliest practical date after the execution of the Securities Purchase Agreement for
the purpose of obtaining stockholder approval for the issuance, in the aggregate, of more than
The Company evaluated the Series M Preferred Stock, the Series M Greenshoe
Rights and the 2026 Warrants under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.
The Series M Preferred Stock is not mandatorily redeemable and is not redeemable at the option of the holder or upon events outside the
Company’s control. Accordingly, the Series M Preferred Stock is classified in permanent equity, and the Series M Greenshoe Rights
are not liabilities under ASC 480. The Series M Greenshoe Rights and the 2026 Warrants are indexed to the Company’s own stock and
meet the conditions for equity classification under ASC 815-40. Their down round features do not affect that conclusion. The net proceeds
of $
Series M Preferred Stock and Warrant Activity During the Nine Months Ended September 30, 2026
During the nine months ended September 30, 2026, the holders of the Company’s
Series M Preferred Stock have converted approximately
Dividends
During
the nine months ended September 30, 2026, the Company declared and paid dividends of approximately $
During
the nine months ended September 30, 2026, the Company declared and paid dividends in cash of approximately $
Note 4 – Common Stock Warrants and Options
Common Stock Warrants
Common Stock warrant transactions for the nine months ended September 30, 2026 were as follows:
Schedule of Common Stock Warrant Transactions
| Nine Months Ended September 30, 2026 | ||||||||
| Number of | Weighted Average | |||||||
| Warrants | Exercise Price | |||||||
| Warrants outstanding at December 31, 2025 | $ | |||||||
| Granted | ||||||||
| Anti-dilution adjustment (1) | ||||||||
| Forfeited/cancelled | ( | ) | ||||||
| Exercised | ( | ) | ||||||
| Warrants outstanding at September 30, 2026 | $ | |||||||
| Warrants exercisable at September 30, 2026 | $ | |||||||
| (1) |
| 13 |
The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of September 30, 2026 was approximately
$
Pursuant
to the May 2025 private placement of Series L Preferred Stock and 2025 Warrants, the Company issued an aggregate of
Pursuant
to the September 2026 private placement of Series M Preferred Stock and 2026 Warrants, the Company issued an aggregate of
In
April 2026, the Company issued pre-funded warrants underlying
Warrants outstanding as of September 30, 2026 are exercisable as follows:
Schedule of Warrants Exercisable
| Warrants Outstanding and Exercisable as of September 30, 2026 | ||||||||||||||
Range of Exercise Price | Number Outstanding | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | |||||||||||
| $ | N/A | $ | ||||||||||||
| 14 |
Common Stock Options
In
April 2022, the Company established the 2022 Omnibus Incentive Plan (the “Plan”) which established the maximum number of
shares of Common Stock that may be issued pursuant to awards granted under the Plan at
Schedule of Options Activity
| Nine Months Ended September 30, 2026 | ||||||||
| Number of | Weighted Average | |||||||
| Options | Exercise Price | |||||||
| Options outstanding at December 31, 2025 | $ | |||||||
| Granted | — | — | ||||||
| Forfeited/cancelled | — | — | ||||||
| Exercised | — | — | ||||||
| Options outstanding at September 30, 2026 | $ | |||||||
| Options exercisable at September 30, 2026 | $ | |||||||
The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2026
was approximately
The
total fair value of options that vested during the nine months ended September 30, 2026 and 2025, was $
Options outstanding as of September 30, 2026 are exercisable as follows:
Schedule of Options Outstanding and Options Exercisable
| Stock Options Exercisable as of September 30, 2026 | ||||||||||||||
Range of Exercise Price | Number Outstanding | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | |||||||||||
| $ | $ | |||||||||||||
Note 5 – Commitments and Contingencies
Litigation
The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business:
TWF Global Matter
On
May 24, 2023, TWF Global, LLC (“TWF”) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes (“Notes”) and
that the Company did not deliver shares of Common Stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a summons and complaint for interpleader
against TWF and Z-One, LLC before the Supreme Court of the State of New York, County of New York, asking the Supreme Court to determine
if the Company’s shares of Common Stock should be registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing
the Company to register the shares of Common Stock in the name of Z-One, LLC and that the Company be released from all associated liability
and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing
of a supplemental party affidavit. On May 9, 2024, Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing
that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company’s shares of Common Stock and there is no
remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of
default. On November 14, 2024, the Court held a hearing on the parties’ motions, at which the Court found that the motion for entry
of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February
17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then
filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder,
either originally or by assignment, of a Convertible Note in the principal amount of $
| 15 |
Silberfein, DiPietro, and Werthman Trust Matters
On
July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $
Significant Agreements
University of Minnesota
2023 Sponsored Research Agreement
On
May 20, 2024, the Company entered into a sponsored research agreement (the “2023 Sponsored Research Agreement”) with the
Regents of the University of Minnesota (the “University of Minnesota”), effective July 1, 2023. Payments totaling approximately
$
On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to instead expire on December 31, 2025. In addition, payments
amounting to $
On
March 26, 2026, the 2023 Sponsored Research Agreement was amended to instead expire on March 31, 2026. In addition, payments
amounting to $
On
August 10, 2026, the 2023 Sponsored Research Agreement was amended to instead expire on December 31, 2026. In addition, payments
amounting to $
| 16 |
The
Company recorded an expense classified as research and development of approximately $
As
of September 30, 2026, there were
2016 Exclusive Patent License Agreement
Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the University of Minnesota (as amended, the “2016
Exclusive Patent License Agreement”), to further develop and commercialize cancer therapies using TriKE® technology
developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the Company receives
exclusive rights to conduct research and to develop, make, use, sell, and import TriKE® technology worldwide for the treatment
of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations,
and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for the regulation
of products such as the TriKE® technology, including without limitation the FDA and the European Agency for the Evaluation
of Medicinal Products in the European Union. The agreement required an upfront payment of $
Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the University of Minnesota (the
“A&R 2016 Exclusive Patent License Agreement”). The amendment required an upfront payment of $
The Company did not record any expense classified as research and development, pursuant to the A&R 2016 Exclusive Patent License Agreement, for the nine months ended September 30, 2026 and 2025.
2021 Exclusive License Agreement
Effective
March 26, 2021, the Company entered into an exclusive license agreement with the University of Minnesota (the “2021 Exclusive Patent
License Agreement”), specific to the B7H3 targeted TriKE®. The agreement required an upfront payment of $
The
Company recorded an expense classified as research and development of approximately $
2024 GTB-3650 Clinical Trial Agreement
On
November 18, 2024, the Company entered into an investigator initiated clinical trial agreement (the “2024 Clinical Trial Agreement”)
with the University of Minnesota, pursuant to which, the University of Minnesota shall sponsor an IND application for IND 165546 GTB-3650
(the “Research Program”) and shall serve as a sponsor investigator for a phase 1 clinical trial entitled, “GTB-3650
(CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed
Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,” designed by the University of Minnesota (the “Study”).
The Research Program is being conducted for clinical research use. The budget for the Study, including without limitations, funding and
resources, provides for up to approximately $
| 17 |
The
Company recorded an expense classified as research and development of approximately $
As
of September 30, 2026, the Company’s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of September 30, 2026, amounted to approximately
$
2026 GTB-5550 Clinical Trial Agreement
On
April 3, 2026, the Company entered into an Investigator Initiated Clinical Trial Agreement (the “2026 GTB-5550 Clinical Trial Agreement”)
with the University of Minnesota, pursuant to which, the University of Minnesota shall sponsor an IND application for IND 169118 GTB-5550
(the “Research Program”) and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, “GTB-5550,
a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy,”
designed by the University of Minnesota (the “Study”). The Research Program is being conducted for clinical research use.
The budget for the Study, including without limitations, funding and resources, provides for up to approximately $
The
Company recorded an expense classified as research and development of approximately $
As
of September 30, 2026, the Company’s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2026 GTB-5550 Clinical Trial Agreement for services that have not yet been rendered as of September 30, 2026, amounted
to approximately $
Advisory Agreement
On
June 30, 2025, the Company entered into an Advisory Agreement (the “Advisory Agreement”) with PDPC Advisors Inc.
(“PDPC”), to perform certain advisory services. Under the Advisory Agreement cash payments amounting to $
On
April 1, 2026, the Company entered into an Amended and Restated Advisory Agreement (the “Amended Advisory Agreement”) with
PDPC, to perform certain advisory services. Under the Amended Advisory Agreement, cash payments amounting to $
On
September 30, 2026, the Company entered into Amendment One to the Amended Advisory Agreement with PDPC which included $
Contingency – NASDAQ Matters
On
November 20, 2025, the Company received a letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”)
of Nasdaq notifying the Company that its Common Stock
| 18 |
In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Letter, or until May 19, 2026, to regain compliance with the Minimum Bid Price Requirement. On May 20, 2026, the Company received
a letter from the Staff notifying the Company that the Staff granted the Company an additional compliance period of 180 calendar days,
or until November 16, 2026, to regain compliance with the Minimum Bid Price Requirement. On September 22, 2026, the Company received
notice from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement under the Nasdaq listing rules. The Company’s
Common Stock maintained a closing bid price above $
There can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement or other applicable Nasdaq listing rules.
If the Common Stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility in the Common Stock and could harm our business and future prospects. In addition, we believe that, if the Common Stock is delisted, our stockholders would likely find it more difficult to obtain accurate quotations as to the price of the Common Stock and it may be more difficult for stockholders to buy or sell shares of Common Stock at competitive market prices, or at all.
Note 6 – Segment Information
The
Company operates and manages its business as
The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.
Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:
Schedule of Segment Information
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| Salaries | ||||||||||||||||
| Insurance | ||||||||||||||||
| Stock-based compensation | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Loss on initial recognition of Greenshoe Rights liability | — | — | — | |||||||||||||
| Change in fair value of Greenshoe Rights liability | — | ( | ) | — | ( | ) | ||||||||||
| Other expense (income) | ( | ) | ( | ) | ||||||||||||
| Net loss (income) | $ | $ | ( | ) | $ | $ | ||||||||||
Note 7 – Subsequent Events
Conversion of Series L Preferred Stock
From
October 1, 2026 through November 10, 2026, the holders of the Company’s Series L Preferred Stock have converted approximately
Silberfein, DiPietro, and Werthman Trust Matters
In
October 2026, the Company settled all claims in the litigation by issuing approximately
November 11, 2026 Special Meeting of Stockholders
On November 11, 2026 stockholders voted (i) to
approve an amendment and restatement of the Company’s Charter, to eliminate sections referencing the Company’s series of
preferred stock that are no longer designated, issued or outstanding, at any time on or prior to November 11, 2027, (ii) to approve
an increase in the Company’s authorized shares of Common Stock, par value $
| 19 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as “believe,” “will,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “may,” “guidance,” “estimate,” “potential,” “outlook,” “target,” “forecast,” “likely” or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. You should carefully review all information, including the discussion of risk factors under “Part I. Item 1A: Risk Factors” and “Part II. Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Form 10-K for the year ended December 31, 2025. Any forward-looking statements in the Form 10-Q are made only as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained in this Form 10-Q to reflect subsequent events or circumstances.
Overview
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”). Once bound to an NK cell, our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cell’s death. TriKE®s can be designed to target any number of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific customization. We believe our TriKE® and Dual Targeting TriKE® platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications. Our preclinical data suggests that this is explained by the TriKE® dependent CD16 directed IL-15 proliferation of NK cells, with little effect on endogenous T cells.
We are using our TriKE® platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational new drug (“IND”) ready moieties in a timely manner after a specific TriKE® conceptual design. Specific drug candidates can then be advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKE®s may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.
Our initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Professor of Medicine, and the Interim Director at the Masonic Cancer Center. Dr. Miller, who also serves as our Consulting Senior Medical Director, is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive rights to the TriKE® platform and are generating additional intellectual property for specific moieties.
| 20 |
Our current product candidate pipeline (as of September 30, 2026) is summarized in the table below:

GTB-3550
GTB-3550 was our first TriKE® product candidate and its clinical development was suspended so that we could focus resources on second-generation TriKEs®. GTB-3550 is a tri-specific killer engager, or TriKE, comprised of two single-chain variable fragments (“scFv”) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We studied this anti-CD16-IL-15-anti-CD33 TriKE® in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (“AML”) and myelodysplastic syndrome (“MDS”). The anti-CD33 antibody fragment in GTB-3550 was derived from the M195 humanized anti-CD33 scFv. We believe the approval of the antibody-drug conjugate gemtuzumab validates the targeting of CD33.
We previously announced the interim clinical trial results for GTB-3550, which showed significantly reduced CD33+ bone marrow blast levels by 33.3%, 61.7%, 63.6%, 50% in Patient 5 (25 µg/kg/day), Patient 7 (50 µg/kg/day), Patient 9 (100 µg/kg/day), and Patient 11 (150 µg/kg/day), respectively. After the end of infusion, GTB-3550 and IL-15 concentrations declined rapidly with overall geometric mean terminal phase elimination half-life (T1/2) of 2.2 and 2.52 hours, respectively. There was minimal CRS resulting from hyperactivation of patient’s T-cell population at doses 5–150 µg/kg/day.
Despite the positive interim clinical trial results, GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKE®, GTB-3650, that similarly targets CD33 on relapsed/refractory AML and high-risk MDS. A key difference between GTB-3550 and GTB-3650 is the incorporation of camelid antibody technology instead of a scFv; our preclinical experience showed markedly enhanced potency of TriKEs® comprised of camelid components. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the second-generation, camelid-based TriKE® platform.
| 21 |

Second Generation TriKE®s Utilize Camelid Nanobody Technology
Our goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred to as nanobodies) are smaller than human immunoglobulin, consisting of two heavy chains instead of two heavy and two light chains. These nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing this camelid antibody structure for all of our new TriKE® product candidates.
| 22 |
To develop second generation TriKE®s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of engaging without the need of a light chain counterpart (see figure below).

These single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFNγ with the single-domain CD16 TriKE® (cam 16-wt15-33; GTB-3650) compared to the original TriKE® (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr. Felices M et al (2020) in Cancer Immunol Res.
CD33+ HL60 Targets in Killing Assays
The purple line represents the GTB-3650 and the blue line represents GTB-3550.

GTB-3650
GTB-3650 is a TriKE® which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650. The TriKE® approach provides a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting, in an anti-CD33-targeted fashion. We are advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We advanced GTB-3650 through requisite preclinical studies and filed an IND application with the U.S. Food and Drug Administration (the “FDA”) in December 2023. In late June 2024, the FDA cleared our IND Application for GTB-3650. We started study enrollment targeting patients with relapsed/refractory AML and high grade MDS on January 21, 2025, and we have advanced into the clinic with the first 4 cohorts now enrolled. This initial study is testing GTB-3650 as monotherapy testing administration 2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy, as agreed on with the FDA.

| 23 |
GTB-5550
GTB-5550 is a B7-H3 targeted TriKE® which targets B7-H3 on the surface of advanced solid tumors (figure above). GTB-5550 is our first dual camelid TriKE®. B7-H3 is expressed on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumors, including head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer (amongst others).
We advanced GTB-5550 through requisite preclinical studies and filed an IND application with the FDA in October 2023 with a written response from the FDA in December 2023. The main question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. In early January 2026, the FDA cleared our IND Application for GTB-5550, and our first patient was dosed in May 2026. The initial trial is designed as a basket trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion).

GTB-7550
GTB-7550 TriKE® is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKE® is a tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv engager against CD19 on malignant and normal B cells, and a human IL-15 sequence between them.
Published data shows that GTB-7550 effectively targets CD19+ malignant cell lines and primary chronic lymphocytic leukemia. Preliminary data shows that GTB-7550 can target and eliminate normal B cells, which we are continuing to test in mice. We are currently exploring and assessing potential manufacturers of GTB-7550.
Critical Accounting Policies
The preparation of our financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments and uncertainties.
| 24 |
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities, assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation of deferred tax assets. Actual results could differ from those estimates.
Stock-Based Compensation
We periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.
Stock-based payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
Results of Operations
Comparison of the Three and Nine Months Ended September 30, 2026 and 2025
Operating Expenses
| Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | $ | 1,710,000 | $ | 634,000 | $ | 1,076,000 | 170 | % | ||||||||
| Selling, general and administrative | 1,751,000 | 2,369,000 | (618,000 | ) | (26 | )% | ||||||||||
| Stock compensation | 46,000 | 379,000 | (333,000 | ) | (88 | )% | ||||||||||
| Total Operating Expenses | $ | 3,507,000 | $ | 3,382,000 | $ | 125,000 | 4 | % | ||||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | $ | 3,178,000 | $ | 2,096,000 | $ | 1,082,000 | 52 | % | ||||||||
| Selling, general and administrative | 7,551,000 | 4,345,000 | 3,206,000 | 74 | % | |||||||||||
| Stock compensation | 138,000 | 386,000 | (248,000 | ) | (64 | )% | ||||||||||
| Total Operating Expenses | $ | 10,867,000 | $ | 6,827,000 | $ | 4,040,000 | 59 | % | ||||||||
Research and Development Expenses
Research and development expenses increased by approximately $1.1 million for the three and nine months ended September 30, 2026 compared to the same prior year periods, primarily due to an increase in material costs in both periods.
Research and development expenses relate to our continued licensing, development, production, and clinical trials of our most advanced TriKE® product candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA with respect to our IND Application in relation to our next generation GTB-3650 camelid nanobody product. Study enrollment began in early 2025 and we have advanced into the clinic with the first 4 cohorts now enrolled. In late January 2026, we received clearance from the FDA with respect to our IND Application in relation to GTB-5550, with a Phase 1 dose escalation basket trial with the first patient dosed in May 2026.
Selling, General and Administrative Expenses
Selling, general and administrative expenses decreased by approximately $0.6 million for the three months ended September 30, 2026 compared to the same prior year period, primarily due to a decrease in consulting fees, and to a lesser extent, marketing expenses.
Selling, general and administrative expenses increased by approximately $3.2 million for the nine months ended September 30, 2026 compared to the same prior year period, primarily due to an increase in marketing expenses, and to a lesser extent, legal and consulting fees.
| 25 |
Other Income (Expense)
| Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Other Income (Expense): | ||||||||||||||||
| Interest income | $ | 39,000 | $ | 36,000 | $ | 3,000 | 8 | % | ||||||||
| Interest expense | (63,000 | ) | — | (63,000 | ) | (100 | )% | |||||||||
| Loss on initial recognition of Greenshoe Rights liability | — | — | — | — | % | |||||||||||
| Change in fair value of Greenshoe Rights liability | — | 11,413,000 | (11,413,000 | ) | (100 | )% | ||||||||||
| Change in fair value of warrant liability | — | 232,000 | (232,000 | ) | (100 | )% | ||||||||||
| Other income | — | — | — | — | % | |||||||||||
| Total Other Income (Expense) | $ | (24,000 | ) | $ | 11,681,000 | $ | (11,705,000 | ) | (100 | )% | ||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Other Income (Expense): | ||||||||||||||||
| Interest income | $ | 164,000 | $ | 106,000 | $ | 58,000 | 55 | % | ||||||||
| Interest expense | (190,000 | ) | — | (190,000 | ) | — | % | |||||||||
| Loss on initial recognition of Greenshoe Rights liability | — | (28,736,000 | ) | 28,736,000 | 100 | % | ||||||||||
| Change in fair value of Greenshoe Rights liability | — | 11,413,000 | (11,413,000 | ) | (100 | )% | ||||||||||
| Change in fair value of warrant liability | 11,000 | 244,000 | (233,000 | ) | (95 | )% | ||||||||||
| Gain on settlement of vendor payable | — | 998,000 | (998,000 | ) | (100 | )% | ||||||||||
| Other income | — | 156,000 | (156,000 | ) | (100 | )% | ||||||||||
| Total Other Income (Expense) | $ | (15,000 | ) | $ | (15,819,000 | ) | $ | 15,804,000 | 100 | % | ||||||
Loss on initial recognition and change in fair value of Greenshoe Rights liability
The Greenshoe Rights connected to the Series L Preferred Stock issued in the May 2025 equity offering contained a pricing reset feature that required classification as a liability and marked to market at each reporting date as required under GAAP.
Gain on Settlement of Vendor Payable
In March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company’s prior year unpaid fees by approximately $1 million.
Net Loss
| Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Net Income (Loss) | $ | (3,531,000 | ) | $ | 8,299,000 | $ | (11,830,000 | ) | (143 | )% | ||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Net Loss | $ | (10,882,000 | ) | $ | (22,646,000 | ) | $ | 11,764,000 | 52 | % | ||||||
Net loss increased by approximately $11.8 million for the three months ended September 30, 2026, compared to the same prior year period, primarily due to the prior year Change in fair value of Greenshoe Rights liability of $11.4 million which did not occur in the current period.
Net loss decreased by approximately $11.8 million for the nine months ended September 30, 2026, compared to the same prior year period, primarily due to the prior year net other expense connected to the Greenshoe Rights liability of $17.3 million which did not occur in the current period, slightly offset by an increase in research and development, and selling, general and administrative expenses, as described above.
| 26 |
Liquidity and Going Concern Analysis
The accompanying unaudited condensed financial statements have been prepared assuming that we will continue as a going concern. We do not have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained operating losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed our operations through public and private sales of Common Stock, the issuance of preferred stock and Common Stock, the issuance of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2026, we recorded a net loss of approximately $10.9 million and used cash in operations of approximately $9.4 million. These factors raise substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Cash Flows
Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Statements of Cash Flow Data: | ||||||||
| Net cash used in operating activities | $ | (9,366,000 | ) | $ | (8,893,000 | ) | ||
| Net cash provided by investing activities | — | — | ||||||
| Net cash provided by financing activities | 12,478,000 | 7,470,000 | ||||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | 3,112,000 | (1,423,000 | ) | |||||
| Cash and cash equivalents and restricted cash, beginning of period | 6,905,000 | 4,044,000 | ||||||
| Cash and cash equivalents and restricted cash, end of period | $ | 10,017,000 | $ | 2,621,000 | ||||
Operating Activities
Net cash used in operating activities was approximately $9.4 million for the nine months ended September 30, 2026 and was primarily due to a net loss of $10.9 million.
Net cash used in operating activities was approximately $8.9 million for the nine months ended September 30, 2025 and was primarily due to a net loss of $22.6 million, offset by a non-cash net other expense connected to the Greenshoe Rights liability of $17.3 million.
Financing Activities
Net cash provided by financing activities was approximately $12.5 million and $7.5 million for the nine months ended September 30, 2026 and 2025, respectively, and resulted primarily from net proceeds from issuance of Series L and M Preferred Stock and exercise of warrants.
Working Capital
The following table summarizes total current assets, liabilities, and working capital for the periods ended September 30, 2026 and December 31, 2025:
| As of | ||||||||||||
September 30, 2026 | December 31, 2025 | Increase/(Decrease) | ||||||||||
| Current assets | $ | 10,568,000 | $ | 8,106,000 | $ | 2,462,000 | ||||||
| Current liabilities | $ | 2,765,000 | $ | 2,319,000 | $ | 446,000 | ||||||
| Working capital | $ | 7,803,000 | $ | 5,787,000 | $ | 2,016,000 | ||||||
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements as of September 30, 2026.
| 27 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our Company qualifies as a smaller reporting company, as defined in 17 C.F.R. §229.10(f)(1) and is not required to provide information for this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our Principal Executive Officer and Principal Financial Officer evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2026. Based on that evaluation, we concluded that our disclosure controls and procedures were not effective as of September 30, 2026, due to a material weakness in internal control over financial reporting that was previously identified for the year ended December 31, 2025, and has not been fully remediated.
Previously Reported Material Weakness
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
As described in Item 9A. “Controls and Procedures” of our Annual Report on Form 10-K for the year ended December 31, 2025, management identified a material weakness related to the Company’s failure to maintain effective controls over the accounting for complex financial transactions, specifically the proper application of ASC 480, Distinguishing Liabilities from Equity, related to certain Greenshoe Rights.
Remediation of Previously Reported Material Weakness
Subsequent to September 30, 2025, the Company implemented additional controls requiring that, prior to the execution of transactions involving stock purchase rights, derivative financial instruments, or other complex financial arrangements, management engages a qualified accounting consultant to evaluate the related accounting treatment and financial reporting implications.
While management believes these controls are appropriately designed, the material weakness will not be considered fully remediated until the controls have operated for a sufficient period of time and management has completed testing to conclude that the controls are operating effectively.
The Company will continue to monitor the effectiveness of its remediation efforts and will make refinements as necessary.
Inherent Limitations on the Effectiveness of Controls
Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal controls over financial reporting during the most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 28 |
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
TWF Global Matter
On May 24, 2023, TWF Global, LLC (“TWF”) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes (“Notes”) and that the Company did not deliver shares of Common Stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a summons and complaint for interpleader against TWF and Z-One, LLC before the Supreme Court of the State of New York, County of New York, asking the Supreme Court to determine if the Company’s shares of Common Stock should be registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of Common Stock in the name of Z-One, LLC and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company’s shares of Common Stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. On November 14, 2024, the Court held a hearing on the parties’ motions, at which the Court found that the motion for entry of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder, either originally or by assignment, of a Convertible Note in the principal amount of $150,000, that the Company breached the Convertible Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it damages in excess of $500,000. On August 26, 2025, the Company filed a motion to dismiss the Complaint in its entirety for lack of standing and failure to state a cause of action. On February 27, 2026, the court issued a Decision and Order granting the Company’s motion and dismissing the claims asserted in the Complaint in their entirety and with prejudice. On March 26, 2026, Z-One, LLC filed a notice of appeal of the February 27, 2026 dismissal. The deadline for Z-One to perfect its appeal was September 28, 2026. Since Z-One, LLC did not perfect its appeal or apply for an extension by that deadline, the appeal is deemed dismissed without further order under 22 NYCRR § 1250.10(a).
Silberfein, DiPietro, and Werthman Trust Matters
On July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $100,000. On July 8, 2025, Justin DiPietro filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $100,000. On July 9, 2025, Phillip Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $100,000. The three summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that the Company breached the convertible notes by failing to deliver shares of Common Stock due on conversion in 2021. Plaintiffs are seeking specific performance and damages. On August 12, 2025, the Company filed demands that the plaintiffs serve complaints. On September 2, 2025, each plaintiff served a Complaint similar in substance to the summons, except that Plaintiff Silberfein now alleges breach of a convertible note with a principal amount of $150,000, rather than $100,000. Each plaintiff alleges that the Company breached a convertible note by failing to deliver conversion shares to the plaintiff holder, and that the Company owes damages in excess of $500,000. In October 2026, the parties reached a settlement resolving all claims in the litigation. Each plaintiff filed a notice of discontinuance with prejudice on October 23, 2026, concluding the matters.
Item 1A. Risk Factors
There have been no material changes from the risk factors disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the third quarter of 2026, the Company issued securities in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, in the amounts and for the consideration set forth below:
On September 28, 2026, the Company issued 16,486 shares of Common Stock to settle $118,000 of vendor accounts payable. The shares were valued at the month-end closing price of the Company’s Common Stock for the months for which services were provided by the vendor.
On September 29, 2026, the Company issued an aggregate of 1,969 shares of Common Stock to the holders of Series L Preferred Stock of record as of October 1, 2026 as a dividend, which represents 12% of the outstanding stated value of the Series L Preferred Stock during the three months ended September 30, 2026.
Any other issuances of unregistered equity securities during the three months ended September 30, 2026 have previously been disclosed in filings with the SEC.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
Rule 10b5-1 Trading Plans
During
the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange
Act of 1934, as amended)
| 29 |
Item 6. Exhibits
| Exhibit | Description | Filed Herewith | Form | Number | SEC File No. | Filing Date | ||||||
| 3.1 | Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002 | 10-KSB | 3.A | 000-08092 | 4/1/2002 | |||||||
| 3.2 | Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011 | 10-K | 3.2 | 000-08092 | 3/31/2011 | |||||||
| 3.3 | Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017 | 8-K/A | 3.1 | 000-08092 | 3/15/2018 | |||||||
| 3.4 | Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021 | 8-K | 3.1 | 001-40023 | 2/11/2021 | |||||||
| 3.5 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022 | 10-K | 3.5 | 001-40023 | 3/30/2023 | |||||||
| 3.6 | Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024 | 8-K | 3.1 | 001-40023 | 2/1/2024 | |||||||
| 3.7 | Amended and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022 | 8-K | 3.1 | 001-40023 | 11/9/2022 | |||||||
| 3.8 | Amendment No. 1 to the Amended and Restated Bylaws of GT Biopharma, Inc. | 8-K | 3.1 | 001-40023 | 6/12/2026 | |||||||
| 3.9 | Certificate of Elimination relating to the Series A Preferred Stock, dated September 2, 2026 | 8-K | 3.1 | 001-40023 | 9/3/2026 | |||||||
| 3.10 | Certificate of Elimination relating to the Series B Preferred Stock, dated September 2, 2026 | 8-K | 3.2 | 001-40023 | 9/3/2026 | |||||||
| 3.11 | Certificate of Elimination relating to the Series C Preferred Stock, dated September 2, 2026 | 8-K | 3.3 | 001-40023 | 9/3/2026 | |||||||
| 3.12 | Certificate of Elimination relating to the Series D Preferred Stock, dated September 2, 2026 | 8-K | 3.4 | 001-40023 | 9/3/2026 | |||||||
| 3.13 | Certificate of Elimination relating to the Series E Preferred Stock, dated September 2, 2026 | 8-K | 3.5 | 001-40023 | 9/3/2026 | |||||||
| 3.14 | Certificate of Elimination relating to the Series F Preferred Stock, dated September 2, 2026 | 8-K | 3.6 | 001-40023 | 9/3/2026 | |||||||
| 3.15 | Certificate of Elimination relating to the Series G Preferred Stock, dated September 2, 2026 | 8-K | 3.7 | 001-40023 | 9/3/2026 | |||||||
| 3.16 | Certificate of Elimination relating to the Series H Preferred Stock, dated September 2, 2026 | 8-K | 3.8 | 001-40023 | 9/3/2026 | |||||||
| 3.17 | Certificate of Elimination relating to the Series I Preferred Stock, dated September 2, 2026 | 8-K | 3.9 | 001-40023 | 9/3/2026 | |||||||
| 3.18 | Certificate of Elimination relating to the Series J-1 Preferred Stock, dated September 2, 2026 | 8-K | 3.10 | 001-40023 | 9/3/2026 | |||||||
| 3.19 | Certificate of Elimination relating to the Series K Preferred Stock, dated September 2, 2026 | 8-K | 3.11 | 001-40023 | 9/3/2026 | |||||||
| 3.20 | Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective September 8, 2026 | 8-K | 3.12 | 001-40023 | 9/3/2026 | |||||||
| 4.1 | Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 12, 2025 | 8-K | 3.1 | 001-40023 | 5/13/2025 | |||||||
| 4.2 | Certificate of Increase to Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 21, 2025 | 8-K | 3.1 | 001-40023 | 5/27/2025 | |||||||
| 4.3 | Form of Waiver | 8-K | 10.1 | 001-40023 | 9/23/2025 | |||||||
| 4.4 | Form of Pre-Funded Common Stock Purchase Warrant | S-1 | 4.49 | 333-291060 | 10/24/2025 |
| 30 |
| 4.5 | Form of Pre-Funded Common Stock Purchase Warrant | 10-Q | 4.7 | 001-40023 | 8/14/2026 | |||||||
| 4.6 | Certificate of Designation of Preferences, Rights and Limitations of Series M 10% Convertible Preferred Stock. | 8-K | 3.1 | 001-40023 | 9/15/2026 | |||||||
| 4.7 | Certificate of Increase to Certificate of Designation of Preferences, Rights and Limitations of Series M 10% Convertible Preferred Stock. | 8-K | 3.1 | 001-40023 | 9/21/2026 | |||||||
| 4.8 | Form of Common Warrant | 8-K | 4.1 | 001-40023 | 9/15/2026 | |||||||
| 4.9 | Form of Vesting Warrant | 8-K | 4.2 | 001-40023 | 9/15/2026 | |||||||
| 10.1 | Investigator Initiated Clinical Trial Agreement, dated as of April 3, 2026, by and between GT Biopharma, Inc. and the Regents of the University of Minnesota. | 8-K | 10.1 | 001-40023 | 4/7/2026 | |||||||
| 10.2 | Securities Purchase Agreement, dated as of September 14, 2026, between the Company and the purchasers identified therein. | 8-K | 10.1 | 001-40023 | 9/15/2026 | |||||||
| 10.3 | Registration Rights Agreement, dated as of September 14, 2026, between the Company and the purchasers identified therein. | 8-K | 10.2 | 001-40023 | 9/15/2026 | |||||||
| 10.4 | Form of Voting Agreement | 8-K | 10.3 | 001-40023 | 9/15/2026 | |||||||
| 10.5 | Form of Lock-up Agreement. | 8-K | 10.4 | 001-40023 | 9/15/2026 | |||||||
| 10.6 | First Amendment to Securities Purchase Agreement, dated as of September 18, 2026, between the Company and the purchasers identified therein. | 8-K | 10.1 | 001-40023 | 9/21/2026 | |||||||
| 10.7 | Joinder to Registration Rights Agreement, dated as of September 18, 2026, between the Company and the purchaser identified therein. | 8-K | 10.2 | 001-40023 | 9/21/2026 | |||||||
| 10.8 | Amendment to the 2022 Omnibus Incentive Plan | X | DEF 14A | Appendix B | 001-40023 | 7/2/2026 | ||||||
| 10.9 | Amendment to the 2022 Omnibus Incentive Plan | X | DEF 14A | Appendix C | 001-40023 | 7/2/2026 | ||||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended. | * | ||||||||||
| 31.2 | Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended. | * | ||||||||||
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* | X | ||||||||||
| 32.2 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* | X | ||||||||||
| 101.INS | Inline XBRL Instance Document. | X | ||||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase | X | ||||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase | X | ||||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase | X | ||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X |
| * | This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act. |
| 31 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| GT BIOPHARMA, INC. | ||
| Dated: November 16, 2026 | By: | /s/ Michael Breen |
| Michael Breen | ||
Chief
Executive Officer and | ||
| (Principal Executive Officer) | ||
| Dated: November 16, 2026 | By: | /s/ Alan Urban |
| Alan Urban | ||
| Chief Financial Officer & Secretary | ||
| (Principal Financial and Accounting Officer) |
| 32 |